RUNX2

Across TCGA pan-cancer cohorts, RUNX2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RUNX2 data layer compared with 32 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher RUNX2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RUNX2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

SKCM, SARC, and PRAD are the cancer types where RUNX2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	IV	0.036	0.433	<.001	12	view →
SARC	DFS	Median	All	0.132	0.617	<.001	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	DFS	Median	All	0.283	0.711	.016	3	view →
UCEC	DFS	Median	All	0.920	0.621	.049	2	view →
COAD	DFS	Median	All	1.000	0.505	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RUNX2–SKCM (DFS)

Open the SKCM breakdown →